Hematuria News and Research

RSS
In medicine, hematuria, or haematuria, is the presence of red blood cells (erythrocytes) in the urine. It may be idiopathic and/or benign, or it can be a sign that there is a kidney stone or a tumor in the urinary tract (kidneys, ureters, urinary bladder, prostate, and urethra), ranging from trivial to lethal.
AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Nearly 7% of urologic MDCT scans for hematuria result in incidental findings

Nearly 7% of urologic MDCT scans for hematuria result in incidental findings

CSI third quarter revenues increase 5% to $21.2 million

CSI third quarter revenues increase 5% to $21.2 million

ASI's GenASIs for detection of chromosomal aberrations in bladder cancer receives FDA approval

ASI's GenASIs for detection of chromosomal aberrations in bladder cancer receives FDA approval

Salix enters definitive agreement to acquire Oceana Therapeutics

Salix enters definitive agreement to acquire Oceana Therapeutics

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

USPTO issues patent for Predictive Biosciences' multiple biomarker assay

USPTO issues patent for Predictive Biosciences' multiple biomarker assay

FDA grants approval for CSI to complete enrollment in ORBIT II IDE coronary clinical trial

FDA grants approval for CSI to complete enrollment in ORBIT II IDE coronary clinical trial

Study provides information about hematuria in microscopic urinalysis and urinary tract cancer

Study provides information about hematuria in microscopic urinalysis and urinary tract cancer

FDA grants CSI marketing clearance for Stealth 360° Orbital PAD System

FDA grants CSI marketing clearance for Stealth 360° Orbital PAD System

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

CSI to present CALCIUM 360° Study results at TCT symposium

CSI to present CALCIUM 360° Study results at TCT symposium

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Researchers identify eight clinical features for cancer

Researchers identify eight clinical features for cancer

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

CSI launches Diamondback Predator 360 catheter system for treatment of peripheral arterial disease

CSI launches Diamondback Predator 360 catheter system for treatment of peripheral arterial disease

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure